2025-06-13-Jefferies-建立实验室公司（ESTA）_ESTA投资者日；重申指引；令人兴奋的产品线；美国推出进展良好_7页_103kb

Company: Establishment Labs (ESTA)
Sector: Medical Technology / Aesthetics
Rating: BUY
Price Target: $61.00 (Up 64% from current price)
Key Takeaways:

1. Positive Investor Day:

   • US market launch progressing well, with daily orders rising steadily.
   • Management reiterated 2025 sales target of $35MM+ and long-term growth outlook.
   • Strong pipeline and innovation cycle (Recon, MIA, Preserve, GEM) expected to drive margin expansion and growth.

2. US Market Performance:

   • 42 reps with plastic surgery experience, >1k surgeons using Motiva.

   • 75% of orders via Motiva Portal, streamlined user experience.

   • Daily order volume averaged ~120 in April (up from 100 in March), trend continues into June.

3. Pricing & Competitive Position:

   • Motiva commands slight premium, justified by quality and safety data.
   • Analysts (e.g., Dr. Mark Epstein) expect ESTA to capture 60-80% US market share in 3 years.

4. International Expansion & Pipeline:

   • OUS environment stable, with pockets of growth in APAC and EMEA (driven by MIA).
   • LatAm market remains challenged despite stabilization.
   • Future product launches (MI Tools, Recon indication) projected to boost margins and revenues.

5. Valuation & Risks:

   • Valuation: $61 PT based on 6-7x 2025 sales.
   • Risks: Macroeconomic conditions, distributor performance, competition, and regulatory delays.

Recommendation:
Jefferies recommends a BUY based on strong US market traction, positive pipeline, and potential for long-term growth despite risks.